Treatment of Barrett's esophagus with high-grade dysplasia.
The incidence of esophageal adenocarcinoma is increasing in the USA, now accounting for at least 4% of US cancer-related deaths. Barrett's esophagus is the main risk factor for the development of esophageal adenocarcinoma. The annual incidence of development of adenocarcinoma in Barrett's esophagus is approximately 0.5% per year, representing at least a 30-40-fold increase in risk from the general population. High-grade dysplasia is known to be the most important risk factor for progression to adenocarcinoma. Traditionally, esophagectomy has been the standard treatment for Barrett's esophagus with high-grade dysplasia. This practice is supported by studies revealing unexpected adenocarcinoma in 29-50% of esophageal resection specimens for high-grade dysplasia. In addition, esophagectomy employed prior to tumor invasion of the muscularis mucosa results in 5-year survival rates in excess of 80%. Although esophagectomy can result in improved survival rates for early-stage cancer, it is accompanied by significant morbidity and mortality. Recently, more accurate methods of surveillance and advances in endoscopic therapies have allowed scientists and clinicians to develop treatment strategies with lower morbidity for high-grade dysplasia. Early data suggests that carefully selected patients with high-grade dysplasia can be managed safely with endoscopic therapy, with outcomes comparable to surgery, but with less morbidity. This is an especially attractive approach for patients that either cannot tolerate or decline surgical esophagectomy. For patients that are surgical candidates, high-volume centers have demonstrated improved morbidity and mortality rates for esophagectomy. The addition of laparoscopic esophagectomy adds a less invasive surgical resection to the treatment armanentarium. Esophagectomy will remain the gold-standard treatment of Barrett's esophagus with high-grade dysplasia until clinical research validates the role of endoscopic therapies. Current treatment strategies for Barrett's esophagus with high-grade dysplasia will be reviewed.
McAllaster
Jennifer D
JD
Department of General Surgery, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mailstop 2005, Kansas City, KS 66160, USA. jmcallaster@kumc.edu
Buckles
Daniel
D
Al-Kasspooles
Mazin
M
D000230:Adenocarcinoma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D001471:Barrett Esophagus / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D017115:Catheter Ablation; D004938:Esophageal Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D016629:Esophagectomy; D004945:Esophagoscopy; D004947:Esophagus / Q000473:pathology*; D006801:Humans; D010778:Photochemotherapy; D015996:Survival Rate